Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.
Video Reports
Smoking, Vitamin D Deficiency Correlate to Ulcerated Melanoma
Ulcerated melanoma is associated with worse outcomes and appears to be driven in part by systemic inflammation, which is more common in smokers, obese individuals, and those with vitamin D deficiency, according to melanoma expert Julia Newton-Bishop, MD, part of a team of investigators exploring genetic and environmental predictors of the immune response in patients with primary cutaneous melanoma.
International Consortium Defines Guidelines for Conducting Neoadjuvant Trials in Melanoma
The use of neoadjuvant therapy prior to surgery has been impactful in breast cancer and other cancer types, but investigators are working to further the reach of neoadjuvant treatment in the melanoma landscape.
BRAF/MEK Inhibitors in Metastatic Melanoma
Jeffrey S. Weber, MD, PhD: We’re talking about BRAF/MEK, but what about the new kids on the block? I mean, encorafenib and binimetinib are relatively recently developed drugs.